← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

FDA approvalNew or expanded indicationHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As subcutaneous monotherapy in the first-line treatment course for adults with unresectable or metastatic hepatocellular carcinoma following IV nivolumab plus ipilimumab combination therapy.

LAMPGEN ANALYSIS

Why it matters

This approval adds a subcutaneous continuation option after first-line IV dual immunotherapy.

What research teams should watch

Map the handoff after the combination phase and distinguish continuation from concurrent use with ipilimumab.

PRIMARY RECORDS

Sources